As a second example, among six patients with refractory AML treated with 2nd generation CD28-ζ-EGFRt+ CAR T cells (MB-102) after lymphodepleting chemotherapy with fludarabine/cyclophosphamide, responses were noted in five, with three exhibiting morphological responses [67]. Here, CD28 is linked to acute myeloid leukemia.